<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214265</url>
  </required_header>
  <id_info>
    <org_study_id>EMK0708C</org_study_id>
    <nct_id>NCT01214265</nct_id>
  </id_info>
  <brief_title>A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive Bladder</brief_title>
  <official_title>A Pilot Clinical Study to Evaluate the Initial Feasibility of Neuromodulation Therapy in Treating Patients With Overactive Bladder Via Magnetic Stimulation of the Posterior Tibial Nerve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMKinetics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMKinetics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and feasibility of non-invasive magnetic stimulation of the posterior
      tibial nerve using the EMKinetics LoFIT Pulse System for treating patients with documented
      overactive bladder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Response Assessment</measure>
    <time_frame>After 12 weeks of therapy</time_frame>
    <description>Improved score on the Global Response Assessment (GRA) scale after 12 weeks of therapy. A score of 2 (moderately improved) or 3 (markedly improved) constitutes a responder on the 7 point scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Frequency</measure>
    <time_frame>After 12 weeks of therapy</time_frame>
    <description>Change in Urinary Frequency (Voiding Diary) from Baseline to 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Incontinence</measure>
    <time_frame>After 12 weeks of therapy</time_frame>
    <description>Change in Urinary Incontinence (Voiding Diary) from Baseline to 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Symptoms (OAB-q SF)</measure>
    <time_frame>After 12 weeks of therapy</time_frame>
    <description>Change in Overactive Bladder Symptoms (OAB-q SF) from Baseline to 12 weeks</description>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Overactive Bladder</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMKinetics non-invasive Magnetic neurostimulator</intervention_name>
    <description>Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women &gt;18 years of age

          -  A score of &gt; 4 on the OAB-q short form for urgency (question 1)

          -  Average urinary frequency &gt; 10 times in one 24 hour day based on a 3-day voiding diary

          -  Self-reported bladder symptoms present &gt; 3 months

          -  Self-reported failed conservative care (e.g., dietary restriction, fluid restriction,
             bladder training, behavioral modification, pelvic muscle training, biofeedback, etc.)
             or use of antimuscarinics.

          -  Off all anti-muscarinics for at least 2 weeks prior to enrollment

          -  Capable of giving informed consent

          -  Ambulatory and able to use a toilet independently, without difficulty

          -  Capable and willing to follow all study-related procedures

        Exclusion Criteria:

          -  The patient is pregnant or intends to become pregnant during the course of the study.
             (Patients becoming pregnant during the course of the study will immediately be
             terminated from the study.)

          -  The patient has an active urinary tract infection.

          -  Neurogenic bladder

          -  Botox use in bladder or pelvic floor muscles in the past year

          -  Pacemakers or implantable defibrillators

          -  Primary complaint of stress urinary incontinence

          -  Current vaginal infection

          -  Current use of InterStim

          -  Current use of Bion

          -  Current use of TENS in the pelvic region, back or leg

          -  Previously been treated with PTNS

          -  Use of investigational drug/device therapy within the past 4 weeks

          -  Participating or have participated within the past 4 weeks in any clinical
             investigation involving or impacting gynecologic, urinary or renal function

          -  Deemed unsuitable for enrollment in study by the investigators based on subjects'
             history or physical examination

          -  The patient has metal implant from surgery or a metallic foreign body in either leg
             below (distal to) the knee (or permanent metallic tattoo &lt;30cm from left ankle).

          -  The patient has chronic constipation (less than two (2) bowel movements per week)

          -  The patient has history of gastric or urinary retention

          -  The patient has uncontrolled diabetes

          -  Subjects with nerve damage, injury or surgery that would impact either tibial nerve or
             pelvic floor function

          -  The patient is unable or unwilling to sign informed consent

          -  The patient is currently on pharmacologic treatment that could affect bladder function

          -  Known Cystocele &gt;/= to Grade 3 that has not been reduced by treatment (surgery or
             pessary)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Incontinence and Pelvic Support Institute</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Amit Rajguru, MD</name_title>
    <organization>EMKinetics, Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 3, 2015</submitted>
    <returned>August 28, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

